Research Article
Construction of a Drug Safety Assurance Information System Based on Clinical Genotyping
Table 1
Points in first part of dose curve.
| | Sequence | X | Y |
| | 1 | .05 PT | .005 PPC | | 2 | .1 PT | .12 PPC | | 3 | .15 PT | .23 PPC | | 4 | .2 PT | .36 PPC | | 5 | .25 PT | .50 PPC | | 6 | .3 PT | .66 PPC | | 7 | .35 PT | .75 PPC | | 8 | .4 PT | .82 PPC | | 9 | .45 PT | .87 PPC | | 10 | .5 PT | .90 PPC | | 11 | .55 PT | .92 PPC | | 12 | .6 PT | .94 PPC | | 13 | .65 PT | .96 PPC | | 14 | .70 PT | .97 PPC | | 15 | .75 PT | .98 PPC | | 16 | .80 PT | .99 PPC | | 17 | .85 PT | .993 PPC | | 18 | .90 PT | .996 PPC | | 19 | .95 PT | .998 PPC | | 20 | 1.0 PT | 1.0 PPC | | 21 | 1.05 PT | .998 PPC |
|
|
PT = % of peak time
PPC = % of peak plasma concentration.
|
